Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Predicting Response in Women with HR+ Tumors
Anticancer Res; 2016 Oct; Waldrep, Avery, et al
The use of imaging in hormone receptor+ tumors after neoadjuvant chemotherapy may yield little or no additional value than that which is obtained from clinical breast exam, according to a retrospective cohort study involving 84 individuals.
Participants were divided into 4 breast cancer subtypes according to hormone receptor and human epidermal growth factor receptor-2 statuses. Investigators calculated negative predictive value, false-negative and false-positive rates, and positive predictive value for both breast exam and imaging between neoadjuvant chemotherapy and surgery. Among the results:
- Overall, imaging had a higher negative predictive value and a lower false-negative rate than breast exam.
- Exams produced lower false-positive rates.
- Exam predicted pathologic residual disease in HR+ tumors with 96% accuracy in HR+HER2- and 100% accuracy in HR+HER2+ diseases.
- In triple-negative breast cancer, imaging negative predictive value rate was 100% and imaging false-negative rate was 0%.
Waldrep A, Avery E, Rose F, et al. Breast cancer subtype influences the accuracy of predicting pathologic response by imaging and clinical breast exam after neoadjuvant chemotherapy. Anticancer Res. 2016;36(10):5389-5395. doi:10.21873/anticanres.11114.